{"id":"W3166810068","doi":"10.1200/jco.2021.39.15_suppl.tps2661","title":"Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1–specific TCR T-cells in HLA-A*02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Hôpital Maisonneuve-Rosemont","funders":"GlaxoSmithKline","keywords":"Medicine; Internal medicine; Oncology; T-cell receptor; T cell; CD8; Tolerability; Response Evaluation Criteria in Solid Tumors; Synovial sarcoma; Immunology; Cancer; Cancer research; Progressive disease; Sarcoma; Immune system; Pathology; Chemotherapy; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006213591,0.001468739,0.001927159,0.0005632336,0.001125567,0.001291166,0.00233431,0.003104998,0.04827908],"category_scores_gemma":[0.005131077,0.0009151145,0.002178231,0.0006819522,0.0005420155,0.001156147,0.001153529,0.004232291,0.01121321],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002732595,"about_ca_system_score_gemma":0.005157805,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001791757,"about_ca_topic_score_gemma":0.005992852,"domain_scores_codex":[0.9970559,0.001922217,0.0002133779,0.0002311535,0.0002812342,0.0002962357],"domain_scores_gemma":[0.9952003,0.0006155461,0.001191446,0.0008296954,0.0009649697,0.00119794],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5332329,0.03291098,0.006603462,0.004338492,0.001698954,0.0004348661,0.0004043514,0.004906497,0.05207424,0.003420359,0.1721977,0.1877773],"study_design_scores_gemma":[0.295012,0.2821356,0.03411788,0.001317505,0.001151914,0.0006764076,0.0002637778,0.003240908,0.01482106,0.003164833,0.3639719,0.0001263641],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.1521477,0.004522982,0.01764514,0.005528703,0.001303497,0.6870852,0.06325724,0.00187502,0.06663448],"genre_scores_gemma":[0.1207375,0.002456098,0.0242089,0.008065807,0.0005435377,0.770112,0.04671691,0.0003678545,0.02679137],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.04827908,"threshold_uncertainty_score":0.1615096,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2679764927034616,"score_gpt":0.494862312304051,"score_spread":0.2268858196005895,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}